DE60003169D1 - Verfahren zur herstellung von [s-(r*,s*)]-g(b)-[[1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl] amino]-3-pyridinpropansäurederivate - Google Patents

Verfahren zur herstellung von [s-(r*,s*)]-g(b)-[[1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl] amino]-3-pyridinpropansäurederivate

Info

Publication number
DE60003169D1
DE60003169D1 DE60003169T DE60003169T DE60003169D1 DE 60003169 D1 DE60003169 D1 DE 60003169D1 DE 60003169 T DE60003169 T DE 60003169T DE 60003169 T DE60003169 T DE 60003169T DE 60003169 D1 DE60003169 D1 DE 60003169D1
Authority
DE
Germany
Prior art keywords
piperidinyl
pyridinpropansäurederivate
oxo
carbonyl
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60003169T
Other languages
English (en)
Other versions
DE60003169T2 (de
Inventor
H Cohen
Michael Justus
Cynthia A Maryanoff
Armin Rossler
Harmen Schroder
L Sorgi
John Villani
Christian Weh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Application granted granted Critical
Publication of DE60003169D1 publication Critical patent/DE60003169D1/de
Publication of DE60003169T2 publication Critical patent/DE60003169T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DE60003169T 1999-03-22 2000-03-21 Verfahren zur herstellung von [s-(r*,s*)]-g(b)-[[1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl] amino]-3-pyridinpropansäurederivate Expired - Fee Related DE60003169T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12567199P 1999-03-22 1999-03-22
US125671P 1999-03-22
PCT/US2000/007462 WO2000056730A1 (en) 1999-03-22 2000-03-21 PROCESS FOR PREPARING [S-(R*,S*)] -β -[[[1-[1-OXO-3- (4-PIPERIDINYL) PROPYL] -3-PIPERIDINYL] CARBONYL] AMINO] -3- PYRIDINEPROPANOIC ACID AND DERIVATIVES

Publications (2)

Publication Number Publication Date
DE60003169D1 true DE60003169D1 (de) 2003-07-10
DE60003169T2 DE60003169T2 (de) 2005-10-27

Family

ID=22420863

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60003169T Expired - Fee Related DE60003169T2 (de) 1999-03-22 2000-03-21 Verfahren zur herstellung von [s-(r*,s*)]-g(b)-[[1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl] amino]-3-pyridinpropansäurederivate

Country Status (22)

Country Link
US (2) US6515130B1 (de)
EP (1) EP1165543B1 (de)
JP (1) JP2002540108A (de)
KR (1) KR20020019895A (de)
CN (1) CN1351600A (de)
AT (1) ATE242235T1 (de)
AU (1) AU775413B2 (de)
BR (1) BR0010652A (de)
CA (1) CA2368024A1 (de)
CZ (1) CZ20013431A3 (de)
DE (1) DE60003169T2 (de)
DK (1) DK1165543T3 (de)
ES (1) ES2199805T3 (de)
HK (1) HK1046272A1 (de)
HR (1) HRP20010767A2 (de)
HU (1) HUP0201262A3 (de)
MX (1) MXPA01009615A (de)
PT (1) PT1165543E (de)
SK (1) SK13562001A3 (de)
UA (1) UA67832C2 (de)
WO (1) WO2000056730A1 (de)
YU (1) YU74601A (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056716A1 (en) 1999-03-22 2000-09-28 Ortho-Mcneil Pharmaceutical, Inc. Synthesis of 3-amino-3-aryl propanoates
MXPA04002629A (es) * 2001-09-21 2005-02-17 Sanofi Aventis Derivados de 2-piridinil-6, 7, 8, 9-tetrahidropirimido [1, 2-a] pirimidin-4-ona y 7-piridinil-2, 3-dihidroimidazo [1, 2-a] pirimidin-5(1h) -ona.
MX352546B (es) 2011-08-17 2017-11-29 Piramal Imaging Sa Compuesto para la union de glicoproteina iib/iiia especifica a plaquetas y su uso para la formacion de imagenes de un trombo.
JP2016508507A (ja) 2013-02-12 2016-03-22 バイエル・ファルマ・アクティエンゲゼルシャフト 血小板特異的糖タンパク質ＩＩｂ／ＩＩＩａに結合するための金属キレート化合物
EP4289819A3 (de) 2013-02-20 2024-01-10 Reuter Chemische Apparatebau e.K. Verfahren zur herstellung von enantiomer angereichertem 3-aminopiperidin
WO2014173855A1 (en) 2013-04-22 2014-10-30 Reuter Chemische Apparatebau Kg Process for preparing enantiomerically enriched 3-hydroxymethylpiperidine
KR102548998B1 (ko) 2020-03-31 2023-06-29 재단법인 아산사회복지재단 혈전영상을 위한 방사성의약품 및 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58243B1 (en) 1983-12-07 1993-08-11 Lonza Ag A process for the preparation of optically-active 3-amino carboxylic acids
US5254573A (en) 1991-10-15 1993-10-19 Monsanto Company Substituted heterocyclic derivatives useful as platelet aggregation inhibitors
DK0669912T3 (da) * 1993-09-22 2002-03-04 Fujisawa Pharmaceutical Co N-(3-Piperidinylcarbonyl)-beta-alaninderivater som PAF-antagonister
US5770575A (en) * 1994-03-16 1998-06-23 Ortho Pharmaceutical Corporation Nipecotic acid derivatives as antithrombotic compounds
WO1997033869A1 (en) * 1996-03-13 1997-09-18 Fujisawa Pharmaceutical Co., Ltd. N-[(r)-1-{3-(4-piperidyl)propionyl-3-piperidylcarbonyl]-2(s)-acetylamino-beta-alanine as fibrinogen receptor antagonist
PL190796B1 (pl) 1996-05-01 2006-01-31 Ortho Mcneil Pharm Inc Karboksyamidowe pochodne piperydyny do leczenia zaburzeń zakrzepicowych
CA2258712C (en) 1996-07-12 2008-01-08 G.D. Searle & Co. Asymetric synthesis of chiral beta-amino acids
US6066651A (en) * 1997-10-29 2000-05-23 Ortho-Mcneil Pharmaceutical, Inc. Orally-active nipecotamide glycolamide esters for the treatment of thrombosis disorders

Also Published As

Publication number Publication date
ATE242235T1 (de) 2003-06-15
DK1165543T3 (da) 2003-09-29
UA67832C2 (uk) 2004-07-15
EP1165543A1 (de) 2002-01-02
EP1165543B1 (de) 2003-06-04
MXPA01009615A (es) 2003-07-21
HU0201262D0 (de) 2002-05-29
KR20020019895A (ko) 2002-03-13
US6515130B1 (en) 2003-02-04
SK13562001A3 (sk) 2002-08-06
AU775413B2 (en) 2004-07-29
HUP0201262A3 (en) 2003-12-29
CN1351600A (zh) 2002-05-29
BR0010652A (pt) 2002-07-16
HRP20010767A2 (en) 2002-12-31
HUP0201262A2 (en) 2002-08-28
PT1165543E (pt) 2003-10-31
YU74601A (sh) 2004-05-12
CZ20013431A3 (cs) 2003-04-16
HK1046272A1 (zh) 2003-01-03
ES2199805T3 (es) 2004-03-01
WO2000056730A1 (en) 2000-09-28
DE60003169T2 (de) 2005-10-27
JP2002540108A (ja) 2002-11-26
CA2368024A1 (en) 2000-09-28
AU3766100A (en) 2000-10-09
US20020137937A1 (en) 2002-09-26

Similar Documents

Publication Publication Date Title
ATE258927T1 (de) Verbessertes verfahren zur herstellung von n- substituierte aminotetraline
DE60214743D1 (de) Verfahren zur herstellung von fischer-tropsch-wachsen
ATE419239T1 (de) Verfahren zur herstellung von 4-phenoxy chinolin derivaten
DE602005026827D1 (de) Verfahren zur herstellung von isoindolderivaten
DE60003169D1 (de) Verfahren zur herstellung von [s-(r*,s*)]-g(b)-[[1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl] amino]-3-pyridinpropansäurederivate
DE60132053D1 (de) Verfahren zur herstellung von amidverbindungen
DE602004025267D1 (de) Verfahren zur herstellung form i von (s)-(+)- clopidogrelbisulfat
DE602004021126D1 (de) Verfahren zur herstellung von n-amino-substituierten heterocyclischen verbindungen
ATE281434T1 (de) Verfahren zur herstellung von benzoperhydroisoindolen
DE602004021605D1 (de) Verfahren zur herstellung von enantiomerenreinem mirtazapin
DE69920708D1 (de) Verfahren zur herstellung von 1,4-bis[[2-(dimethylamino)ethyl amino]-5,8-dihydroxyanthracene-9,10-dion
ATE348810T1 (de) Verfahren zur herstellung von 2-aminomethyl- halogen-pyridinen
ATE310735T1 (de) Verfahren zur herstellung von spirocyclischen tetronsäurederivaten
ATE380173T1 (de) Verfahren zur herstellung von (2s,3r,4s)-4- hydroxyisoleucin und analoga
DE60106778D1 (de) Verfahren zur herstellung von vitronectin-rezeptorantagonisten
ATE496038T1 (de) Verfahren zur herstellung von quetiapin
ATE310734T1 (de) Verfahren zur herstellung von n-substituierten 2, 6-dialkylmorpholinen
DE50103009D1 (de) Verfahren zur herstellung von 2-alkyl-3-chlorphenolen
ATE244706T1 (de) Enantiomere von mercaptolactonen und verfahren zu ihrer herstellung
DE69714875D1 (de) Verfahren zur Herstellung von hetero-bizyklischem Alkohol-Enantiomer
ATE330612T1 (de) Verfahren zur herstellung von benazeprilhydrochloride
DE60001151D1 (de) Lösungsmittelfreies verfahren zur herstellung von thiuram-disulfiden
ATE265463T1 (de) Verfahren zur herstellung von organischen aziden
ATE425143T1 (de) Verfahren zur herstellung von indolen
ATE404540T1 (de) Verfahren zur herstellung von 1-substituierten 5- chlor-4methylpyrazolen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: BOEHMERT & BOEHMERT, 28209 BREMEN

8339 Ceased/non-payment of the annual fee